Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.

Abstract: An assay method for determining transcobalamin saturation wherein a transcobalamin containing liquid sample is contacted with a porous substrate with immobilized thereon a transcobalamin immobilizing ligand and with a reporter-labelled transcobalamin binding partner and wherein signals from reporter labels which become immobilized on said substrate are detected, characterised in that one of same ligand or said binding partner comprises a first ligand or binding partner capable of specific binding to holo transcobalamin and a second ligand or binding partner capable of binding to apo transcobalamin or to holo and apo transcobalamin.

Abstract: The present invention relates to assay methods for the determination of cobalamin or vitamin B12 in a body fluid and in particular to assay methods for the metabolically active pool of cobalamin, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.

Abstract: The invention provides a diagnostic or prognostic assay method for Alzheimer's Disease by assaying a body fluid sample or a test sample derived therefrom for holo-trancobalamin II.

Abstract: The invention provides an assay method for the determination of transcobalamin II (TC II) bound cobalamin in a body sample, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or cobalamin bound TC II (holo TC II), separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.

Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.

Abstract: The present invention relates to assay methods for the determination of cobalamin or vitamin B12 in a body fluid and in particular to assay methods for the metabolically active pool of cobalamin, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.

Abstract: An assay method for the detection of cardiovascular disease, potential cardiovascular disease, megalobastic anemia, hyperhomocysteinemia or potential irreversible neurological disorders, in a human or non-human animal subject, said method comprising assessing, the concentration of both holo-transcobolamin II (holo TCII) and folate in a cobalamin-containing sample from said subject and the optional assessment of total sample cobalamin. A kit for carrying out the assay method is also provided.

Abstract: An assay method for determining transcobalamin saturation wherein a transcobalamin containing liquid sample is contacted with a porous substrate with immobilized thereon a transcobalamin immobilizing ligand and with a reporter-labelled transcobalamin binding partner and wherein signals from reporter labels which become immobilized on said substrate are detected, characterised in that one of same ligand or said binding partner comprises a first ligand or binding partner capable of specific binding to holo transcobalamin and a second ligand or binding partner capable of binding to ape transcobalamin or to holo and apo transcobalamin.

Abstract: The invention provides a diagnostic or prognostic assay method for Alzheimer's Disease which method comprises assaying a body fluid sample or a test sample derived therefrom for holo-trancobalamin II.

Abstract: An assay method comprising the detection of holotranscobalamin II (holo-TCII) and folate in a cobalamin-containing sample from a subject.

Abstract: The present invention relates to assay methods for the determination of cobalamin or vitamin B12 in a body fluid and in particular to assay methods for the metabolically active pool of cobalamin, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.

Abstract: The present invention relates to compounds comprising the amino acid sequences of the formulae (IA): -CVNENGGCEQYCSD-, (IB): -FCLPAFEGRNCE- and/or (IC): -RCHEGYSLLADGVSCT- as well as peptide fragments thereof, esters, amides, salts and cyclic derivatives thereof, functional analogues thereof and extended peptide chains carrying amino acids or peptides at the termini of the above sequences or fragments, for use in the prevention or inhibition of binding of tissue factor to FVII.

Abstract: The present invention relates to disulphide-cyclo-?H-Cys-Glu-Gln-Tyr-Cys-OH! and salts thereof which are useful in the treatment of blood clotting disorders.

Abstract: The present invention relates to peptide of the amino acid sequence of formula (I):82 85 90 Glu Thr His Lys Asp Asp Gln Leu Ile 95 100 Cys Val Asn Glu Asn Gly Gly Cys Glu Gln 105 110 Tyr Cys Ser Asp His Thr Gly Thr Lys Arg 115 120 Ser Cys Arg Cys His Glu Gly Tyr Ser Leu 125 128 Leu Ala Asp Gly Val Ser Cys Thr (SEQ ID NO. 1)and functional equivalents thereof in which amino acids in the above stated sequence are modified or absent and wherein at least one of the cysteine residues may be blocked or replaced and wherein any cysteine residues which remain unblocked or unreplaced may be present in a disulphide bonded state. The invention also includes slats and derivatives of said peptides. The peptides and their salts and derivatives are useful in the treatment of blood clotting disorders.

Abstract: Peptide reagents and compositions thereof which reduce blood clotting initiated by the ternary complex of tissue factor (TF), FVIIa and FXa. The peptides have the amino acid sequences Thr--Leu--Tyr--Tyr--Trp--Arg--Ala--Ser--Ser--Thr (SEQ. ID. NO: 3) and Ile--Ile--Thr--Tyr--Arg--Lys--Gly--Ser--Ser--Thr (SEQ. ID. NO: 2).